^(89)SrCl_2治疗多发性骨转移癌骨痛与ET、CGRP、TXB_2、6-K-PGF_(1a)的关系  

Relationship between therapeutic effects of ^(89)SrCl_2 on osteodynia induced by multiple bone metastases and ET,CGRP,TXB_2 and 6-K-PGF_(1a)

作　　者：孙文伟[1] 魏丽琴[1] 谭平[2] 马庆杰[1] 

机构地区：[1]吉林大学中日联谊医院核医学科,吉林长春130033 [2]吉林大学中日联谊医院呼吸内科,吉林长春130033

出　　处：《吉林大学学报（医学版）》2007年第3期581-583,共3页Journal of Jilin University：Medicine Edition

基　　金：吉林省科技厅自然科学基金资助课题(200505176)

摘　　要：目的:探讨89SrCl2治疗多发性骨转移癌骨痛与内皮素(ET)、降钙素基因相关肽(CGRP)、血栓素B2(TXB2)及6-酮-前列腺素F1a(6-K-PGF1a)的关系。方法:39例多发性骨转移癌患者行89SrCl2内照射治疗,采用放射免疫分析法检测治疗前和治疗后1、3及6个月时患者血浆ET、CGRP、TXB2、6-K-PGF1a含量,并计算ET/CGRP。结果:ET含量,治疗后1个月较治疗前无明显变化,治疗后3及6个月与治疗前及治疗后1个月相比均明显升高(P<0.01);CGRP含量,治疗后1个月与治疗前比较明显升高(P<0.05);ET/CGRP比值,治疗前较治疗后1个月无明显变化,治疗后3及6个月与治疗前及治疗后1个月比较均明显升高(P<0.01);TXB2含量治疗前后无明显变化;6-K-PGF1a含量,治疗前较治疗后1个月无明显变化,治疗后3及6个月与治疗前及治疗后1个月比较均显著升高(P<0.01)。结论:89SrCl2治疗多发性骨转移癌骨痛的止痛作用与ET、CGRP、6-K-PGF1a、以及ET与CGRP的平衡有关。Objective To explore the relationship between therapeutic effects of 89SRCl2 on osteodynia induced by multiple bone metastasis and ET, CGRP, TXI32 and 6-K-PGF1α. Methods 89SrCl2 treatment was used in 39 cases of multiple bone metastasis, the serum content of ET, CGRP, TXB2 and 6-K-PGF1α were detected with radioimmunological method pre-treatment and 1, 3, 6 months post-treatment, respectively; the ET/CGRP value was calculated. Results The content of ET showed no obvious changes 1 month post-treatment compared with pretreatment. However, the ET contents increased significantly 3 and 6 months post-treatment compared with 1 month post-treatment and before treatment （P 〈 0. 01）. CGRP content increased significantly 1 month posttreatment compared with pre-treatment （P 〈 0.05）. However, ET/CGRP value had no significant difference 1 month post-treatment compared with pre-treatment. ET/CGRP increased remarkably 3 and 6 months posttreatment compared with pre-treatment and 1 month post-treatment （P〈 0. 01）. Also, TXB2 content had no significant changes between pre- and post-treatment. While 6-K-PGF1α, content demonstrated no obvious changes 1 month post-treatment compared with pre-treatment. 6-K-PGF1α content increased markedly 3 and 6 months posttreatment compared with pre-treatment and 1 month post-treatment （P〈0.01）. Conclusion The mechanism of releasing pain through 89 SrCl2 strategy is related to ET, CGRP, 6-K-PGF1α and ET/CGRP.

关 键 词：^89SRCL2 多发性骨转移癌 内皮素 降钙素基因相关肽 血栓素B2 6-酮-前列腺素F1A 

分 类 号：R730.55[医药卫生—肿瘤] R730.6[医药卫生—临床医学]